Dignity Sciences Limted
Records under this name other than the patents Dignity Sciences Limted holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 10 of 10 · Back to Dignity Sciences Limted
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,729,126 | Use of pufas for treating skin inflammation Lapsed on the fee record Ended May 20, 2026 · From the USPTO record | Lapsed on the fee record | Ended May 20, 2026 | From the USPTO record |
| US 8,536,223 | Use of PUFAs for treating skin inflammation Lapsed on the fee record Ended Sep 17, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 17, 2025 | From the USPTO record |
| US 9,682,055 | Pharmaceutical compositions comprising DGLA and use of same Lapsed on the fee record Ended Jun 20, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 20, 2025 | From the USPTO record |
| US 8,293,790 | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof Lapsed on the fee record Ended Oct 23, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 23, 2024 | From the USPTO record |
| US 9,439,850 | Use of pufas for treating skin inflammation Lapsed on the fee record Ended Sep 13, 2024 · From the USPTO record | Lapsed on the fee record | Ended Sep 13, 2024 | From the USPTO record |
| US 9,421,163 | Topical compositions comprising polyunsaturated fatty acids Lapsed on the fee record Ended Aug 23, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 23, 2024 | From the USPTO record |
| US 9,216,151 | Use of PUFAS for treating skin inflammation Lapsed on the fee record Ended Dec 22, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 22, 2023 | From the USPTO record |
| US 9,096,815 | Compositions comprising 20-carbon fatty acids and methods of making and using same Lapsed on the fee record Ended Aug 4, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 4, 2023 | From the USPTO record |
| US 9,056,086 | Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETrE and methods of use thereof Lapsed on the fee record Ended Jun 16, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jun 16, 2023 | From the USPTO record |
| US 8,936,803 | Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof Lapsed on the fee record Ended Jan 20, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jan 20, 2023 | From the USPTO record |